Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Therapeutics Inc.

www.amicusrx.com

Latest From Amicus Therapeutics Inc.

US FDA's Stein Outlines Functions Of Rare Disease, Inborn Error Groups In New OND Division

Office of New Drugs director Peter Stein shed some light on how the newly established Division of Rare Diseases and Medical Genetics will operate following the completion of the OND reorganization, drawing mixed reactions from industry speakers.

Leadership FDA

Regenerative Medicines And Advanced Therapies: Progress, Problems And Promise

The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.

Regenerative Medicine Research and Development Strategies

US Pharma Firms Not In Post-Brexit Trade Talks

A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions

United Kingdom Reimbursement

Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a  new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.

Appointments Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amicus Therapeutics Inc.
  • Senior Management
  • John F Crowley, Chmn. & CEO
    Daphne Quimi, CFO
    Jay A Barth, MD, CMO
    Bradley L Campbell, Pres. & COO
    Hung Do, PhD, CSO
  • Contact Info
  • Amicus Therapeutics Inc.
    Phone: (609) 662-2000
    1 Cedar Brook Dr.
    Cranbury, NJ 08512
    USA
UsernamePublicRestriction

Register